Funding Biodefense Vaccine Development - Alternative sources that spin-off companies can tap into. - BioPharm International

ADVERTISEMENT

Funding Biodefense Vaccine Development
Alternative sources that spin-off companies can tap into.


BioPharm International
Volume 22, Issue 4

SUMMARY

A spin-off biodefense vaccine development company seeking growth and start-up funding must generally rely on sources other than traditional founders and their interpersonal networks. The approaches discussed above are not comprehensive and may be combined in a number of ways; funding can take the form of any combination of grants, investments, loans, and alternate strategies such as licensing. Indeed, spin-off companies can maximize their funding successes by pursuing a combination of the sources listed here.

In selecting which funding sources to pursue, spin-off owners should focus on the downside of debt and equity deals, even as they pursue the upside of profits and value growth. The worst-case scenario may not be stifled growth because of a lack of capital; it may instead be substantial personal debt resulting from a failed company, the promise of which, no matter how great, was never realized.

Sandy Weinberg, PhD, is an associate professor of healthcare management at Clayton State University, Morrow, GA, 404.606.0211,

REFERENCES

1. Bell CG, McNamara JE. High-tech ventures: The guide for entrepreneurial success. New York: Perseus Books; 1991. Chapter 4.

2. Bygrave WD, editor. The portable MBA in entrepreneurship. New York: John Wiley and Sons; 1997. Chapter 1.

3. Flanagan J. Successful fundraising. Chicago: Contemporary Books; 1993. Chapter 12.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
FDA and NIH Win Award for IP Licensing of Meningitis Vaccine
September 26, 2014
Author Guidelines
Source: BioPharm International,
Click here